GUIDE TO VERMONT'S PHARMACEUTICAL MARKETER PRICE DISCLOSURE LAW, 18 V.S.A. § 4633

Published by the Vermont Office of the

Attorney General

Final Publication Date: January 13, 2005
Revised February 26, 2005
Effective Date: March 1, 2005

Introduction

Vermont law 18 V.S.A. § 4633 requires pharmaceutical marketers to disclose to Vermont doctors and other prescribers the prices of the drugs they market as well as the prices of others drugs in the same therapeutic class. This Guide to the law, published by the Vermont Attorney General, informs pharmaceutical manufacturers and marketers how to comply with the law.

Contents

I. Law Text
II. Entities Who Must Disclose
III. Activity Triggering Disclosure
IV. Required Disclosure
V. Additional Disclosure Requirements Based Upon Marketing Technique
VI. Required Disclaimers
VII. Submissions to Attorney General Upon Request
Appendix 1: Long Form Disclosure Model
Appendix 2: Short Form Disclosure Model
Appendix 3: 2004 American Hospital Formulary Service Pharmacologic-Therapeutic Classification

I. Law Text

Vermont's Pharmaceutical Marketer Price Disclosure Law, 18 V.S.A. § 4633, provides:

§ 4633. Pharmaceutical marketer price disclosure

(a) When a pharmaceutical marketer engages in any form of prescription drug marketing directly to a physician or other person authorized to prescribe prescription drugs, the marketer shall disclose to the physician or other prescriber the average wholesale price (AWP) of the drugs being marketed. Disclosure shall include the AWP per pill and the price relationship between the drug being marketed and other drugs within the same therapeutic class.

(b) The disclosures required under this section shall be on a form and in a manner prescribed by the office of the attorney general. The attorney general may adopt rules to implement the provisions of this section.

(c) In addition to any other remedy provided by law, the attorney general after consultation with the commissioner of banking, insurance, securities, and health care administration may file an action in superior court for a violation of this section or of rules adopted under this section. In any such action, the attorney general shall have the same authority to investigate and to obtain remedies as if the action were brought under the consumer fraud act, chapter 63 of Title 9. Each violation of this section or of rules adopted under this section constitutes a separate civil violation for which the attorney general may obtain relief.

(d) As used in this section:

(1) "Average wholesale price" or "AWP" means the wholesale price charged on a specific commodity that is assigned by the drug manufacturer and listed in a nationally recognized drug pricing file.

(2) "Pharmaceutical manufacturing company" is defined by subdivision 4632(c)(5) of this title.

(3) "Pharmaceutical marketer" is defined by subdivision 4632(c)(4) of this title. (Added 2003, No. 122 (Adj. Sess.), § 128c; amended 2007, No. 80, § 5.)

(1) II. Entities Who Must Disclose

The law requires disclosures by a "pharmaceutical marketer." Pharmaceutical marketer is defined in 18 V.S.A. § 4632(c)(4) as follows:

> "Pharmaceutical marketer" means a person who, while employed by or under contract to represent a pharmaceutical manufacturing company, engages in pharmaceutical detailing, promotional activities, or other marketing of prescription drugs in this state to any physician, hospital, nursing home, pharmacist, health benefit plan administrator, or any other person authorized to prescribe, dispense, or purchase prescription drugs. The term does not include a wholesale drug distributor or the distributor's representative who promotes or otherwise markets the services of the wholesale drug distributor in connection with a prescription drug.

Thus, the law requires disclosures by persons who, while employed by a pharmaceutical company, or under contract to represent a pharmaceutical company, engage in pharmaceutical detailing, promotional activities or other marketing of prescription drugs in this state.

Pharmaceutical manufacturing company is defined in 18 V.S.A. § 4632(c)(5) as follows:

> "Pharmaceutical manufacturing company" means any entity which is engaged in the production, preparation, propagation, compounding, conversion, or processing of prescription drugs, either directly or indirectly by extraction from substances of natural origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, or any entity engaged in the packaging, repackaging, labeling, relabeling, or distribution of prescription drugs. The term does not include a wholesale drug distributor or pharmacist licensed under chapter 36 of Title 26.

Excluded from the law's disclosure requirements are wholesale drug distributors, as well as the distributor's representative who promotes or otherwise markets the services of the wholesale drug distributor in connection with a prescription drug.

III. Promotional Activities Triggering Disclosure

The law states that disclosures will be required when a pharmaceutical marketer engages in "any form of prescription drug marketing directly to a physician or other person authorized to prescribe prescription drugs." This section describes the activities that are covered by this definition, and the activities that are excluded.

A. Covered promotional activity includes the following activities related to promotion of a prescription drug, when directed to a Vermont physician or other person authorized to prescribe drugs:

1. Mailings into Vermont to Vermont physicians or other persons authorized to prescribe drugs in Vermont, or to members of their staff;
2. Face-to-face meetings in Vermont with physicians or other persons authorized to prescribe drugs in Vermont, or to members of their staff, including promotional talks, and continuing medical education programs not supported by an unrestricted grant from the pharmaceutical marketer or manufacturer;
3. Telephone calls to Vermont to physicians or other persons authorized to prescribe drugs in Vermont, or to members of their staff;
4. E-mails and other electronic communications sent directly to physicians or other persons who reside in Vermont or have their place of business in Vermont, and who are authorized to prescribe drugs in Vermont, or to members of their staff.
5. Hand delivery or shipment of promotional materials, including samples, to physicians or other persons authorized to prescribe drugs in Vermont, or to members of their staff.

B. Activity that is excluded from coverage under the law includes:

1. Advertisements placed in magazines, on television, or in other media.
2. Reminder communications that call attention to the name of a drug product but do not include information about indications or dosage recommendations for use of the product, and that are exempted by FDA from the requirement to disclose drug safety information.
3. Independent continuing medical education programs supported by an unrestricted grant from the pharmaceutical marketer or pharmaceutical manufacturer.
4. Drugs marketed to state or private payers of pharmaceutical benefits.
5. Drugs marketed for use in hospitals or by patients within a health care facility, such as in a diagnostic facility, a dialysis facility, or an outpatient (or "day procedure") setting.
6. Communications by the manufacturer in any of the above forms that are: (i) directly to a physician or other person authorized to prescribe drugs in Vermont, (ii) about the product, and (iii) provided to the prescriber in response to an unsolicited request.

IV. Required Disclosure

There shall be a Long Form and a Short Form disclosure. Section IV (A) describes the requirements that apply to both the Long Form and the Short Form Disclosures. Section

IV(B) describes the requirements of the Long Form disclosure. Section IV (C) describes the requirements of the Short Form disclosure.

A. Requirements for Long Form and Short Form Disclosures.

1. "Average Wholesale Price," or AWP, is defined in the statute as "the wholesale price charged on a specific commodity that is assigned by the drug manufacturer and listed in a nationally recognized drug pricing file." For purposes of this Guide, "Average Wholesale Price" or "AWP" shall mean the Average Wholesale Price published by one of the following sources: (1) First Databank; (2) Medispan (Wolters Klumer Health); or (3) Redbook (Thomson MICROMEDEX). The same source must be used throughout the disclosure form.
2. The disclosure of the AWPs must be on a "per pill" basis. If the drug being marketed is in liquid, aerosol, injectible, or other non-pill form, then there is no disclosure requirement, and the manufacturer is not required to provide a disclosure in accordance with this Guide. If one or more of the related drugs is in liquid, aerosol, injectible or other non-pill form, then the marketer shall list that drug and indicate that it is a "non-pill product", and the AWPs need not be disclosed for that related drug.
3. "Therapeutic Class," for the purposes of this Guide, shall mean the therapeutic class listed in the most recent American Hospital Formulary Service Pharmacologic-Therapeutic Classification, published by American Society of Health System Pharmacists, available at http://www.ashp.org/ahfs (hereinafter "AHFS Classification System"). From March 1, 2005, through December 31, 2005, pharmaceutical marketers may use the 2004 or 2005 American Hospital Formulary Service Pharmacologic-Therapeutic Classification. Secondary subclasses shall not be employed. The appropriate therapeutic class within AHFS Classification System shall be determined by the drug that is being marketed, and shall be the most specific grouping in the AHFS Classification System that applies to the manufacturer's marketed drug. Once the classification of the marketed drug is determined, then all other drugs within the same therapeutic class shall be all other products that fall within the same class of the AHFS Classification System. The 2004 AHFS Classification system is attached as Appendix 3.
4. Pharmaceutical marketers are required to provide pricing information required by this Guide for the smallest package size available for each drug strength listed on the price sheet, excluding unit dose packages (that is, excluding, for example, "blister packs" with tear-off strips).
5. There is no disclosure requirement for a marketed drug if First Databank, Medispan and Redbook *all* do not publish an AWP for the marketed product.

B. Long Form Disclosure. Pharmaceutical marketers who are engaged in relevant promotional activities to physicians and other persons authorized to prescribe prescription drugs in Vermont must make the following disclosures by publishing the following information on a website made available in all circumstances described in Sections III (A) and V. (Hereinafter, the disclosure required by this Section IV(A) is referred to as the "Long Form Disclosure.")

1. The AWP per pill of the drug being marketed and other drugs in the same therapeutic class (hereinafter sometimes referred to as "related drugs") must be disclosed.
2. The disclosed AWP of the drug being marketed and the disclosed AWPs of related drugs must be updated at the same time, and no less than every three months.
3. The Long Form Disclosure must list the source of the AWP information by listing one of the allowable sources set forth in Section IV (A) (1). The Long Form Disclosure must also list the date that the information was obtained from the allowable source.
4. All pill form products must be listed in the Long Form Disclosure, including generics and chewables.
5. With respect to a related drug for which First Databank, Medispan or Redbook does not publish an AWP, the marketer shall indicate on the Long Form Disclosure that its data source does not publish an AWP for that related drug. In such a circumstance, the marketer shall list the AWPs of all other drugs within the same therapeutic class.
6. The Long Form disclosure need not include the AWPs published by repackagers.
7. The Long Form disclosure shall be provided to Vermont prescribers by listing on the Short Form Disclosure the web site where the required information shall be available.
8. The Long Form disclosure shall be titled: "Information for Vermont Prescribers of Prescription Drugs: [INSERT NAME OF MARKETED DRUG]". The Long Form disclosure shall then contain the disclaimers required pursuant to Section VI. The Long Form disclosure shall then contain a table listing the products in the therapeutic class. The columns for the table shall be, from left to right: Product Name, Manufacturer, NDC or UPC, Package Size, and AWP Per Package and AWP Per Pill. The table shall first list the information for the marketed product, with each dosage of the marketed product listed in a separate row, which shall be organized from lowest dosage to highest dosage. The table shall then list the information for all other products in the same therapeutic class. The related products shall be listed in alphabetical order, and each separate product shall be listed from lowest dosage to highest dosage. There shall be a space between the rows for the marketed product and the rows for the other products in the same therapeutic class. After the table, the Long Form disclosure shall contain a statement indicating the source of the AWP information provided on the Long Form disclosure, and the date that the information was obtained from that source.
9. The Long Form disclosure shall be in the form modeled in Appendix 1.

C. Short Form Disclosure. Pharmaceutical marketers who are engaged in relevant promotional activities to physicians and other persons authorized to prescribe prescription drugs in Vermont must make the following disclosures by providing the following information on separate sheet of paper that is no less than 8 V2 inches by 11 inches in size in all circumstances described in Sections III (A) and V. (Hereinafter, the disclosure required by this Section IV(C) is referred to as the "Short Form Disclosure.")

1. The Short Form disclosure shall contain the AWP per pill of the lowest dosage of the marketed drug, the average AWPs per pill of the lowest dosage all multi-source (generic) products in the same therapeutic class, and the AWPs per pill of the lowest dosage of other products in the same therapeutic class.

2. The pharmaceutical marketer must update the information required in Section IV(C) at the same time, and no less than every three months.
3. With respect to a related drug for which First Databank, Medispan or Redbook does not publish an AWP, the Short Form Disclosure shall not include said product on the form, or in the averaging for the generic price disclosure.
4. The Short Form disclosure shall be titled: "Information for Vermont Prescribers of Prescription Drugs (Short Form): [INSERT NAME OF MARKETED DRUG]". The Short Form disclosure shall then contain the disclaimers required pursuant to Section VI. The Short Form disclosure shall then contain the following statement: **"Price Comparison:** Marketed product and lowest dosage of other products in same therapeutic class.*" The Short Form disclosure shall then contain a heading entitled **"Marketed Product",** and shall then list the name and AWP per pill of the lowest dose of the marketed product. The Short Form disclosure shall then contain a heading entitled **"Other Products",** and shall then list the names and AWPs per pill of the lowest dose of all multi-source and single source products in the same therapeutic class. The AWPs for the multi-source products shall be an average of the AWPs of the various manufacturers who produce the product at the same lowest dosage. The products in the "Other Products" listing shall be organized from lowest to highest AWP per pill. The Short Form disclosure shall then contain the following statements:

   *Prices shown are for the lowest dosage of each product. Prices for multi-source products have been averaged. Multiple forms of the same product (e.g. tabs and caps) have been considered one product, and the prices have been averaged. Chewable forms of the product are not included.

   For additional price comparison information see: http:// [INSERT WEB ADDRESS WHERE LONG FORM DISCLOSURE SHALL BE AVAILABLE]

5. In calculating the average AWP for the lowest dosage pill for multi-source products or for a single-source product with multiple forms (e.g. tabs and caps), multiple forms of the same product (tabs and caps) shall be considered one product, and the prices shall be averaged. Chewable forms of the multi-source products shall not be listed or included in the averages. Multi-source products that do not have an AWP listed in First Databank, Medispan and Redbook shall not be included in the averages.
6. The Short Form disclosure shall be in the form modeled in Appendix 2.

<u>Additional Disclosure Requirements Based Upon Marketing Technique</u>

Other aspects of the required disclosures vary based upon the marketing technique

A. *Face-to-Face, In-Person, and Mail Communications:* If the communication with the physician or other persons authorized to prescribe drugs in Vermont is face-to-face, at an in-person meeting, or through the mail, then the pharmaceutical marketer shall provide the physician or other person with a Short Form disclosure, described in Section IV(C). If more than one drug is marketed during the same meeting or through the same mail communication, then a separate Short Form disclosure shall be provided with respect to each marketed drug. If the communication is face-to-face, the Short Form disclosure shall be

provided at the same time as the face-to-face communication. If the communication is through the mail, the Short Form disclosure shall be provided in the same mailing packet that contains the promotional material.

B. *Electronic Communications:* If the communication with the physician or other persons authorized to prescribe drugs in Vermont is electronic, then the electronic communication must contain, either as a readable attachment or in a conspicuous and separate section of the email, the Short Form disclosure, described in Section IV (C). If more than one drug is marketed in the same email, then a separate disclosure in conformity with this Section V(B) shall be provided with respect to each marketed drug. The disclosure described herein must be sent in the same electronic communication that contains the promotional material.

C. *Telephonic Communications:* If the communication with the physician or other persons authorized to prescribe drugs in Vermont is telephonic, then the pharmaceutical marketer must: (i) inform the physician or other prescriber, during the telephonic communication, that the marketer will be sending a price disclosure for each drug that has been marketed; (ii) send to the physician or other prescriber, at his or her place of business and within 24 hours of the telephonic communication, a Short Form disclosure as described in V(A) or V(B) above. If more than one drug is marketed during the same telephonic communication, then a separate Short Form disclosure shall be provided pursuant to this Section V(C) with respect to each marketed drug.

VI. Required Disclaimers

A. The following disclaimers shall be included with both the Long Form and Short Form disclosures required under Vermont's Pharmaceutical Price Disclosure Law and this Guide. These disclaimers shall appear before the list of products and prices required by this Guide.

1. "This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information."

2. "The prices listed below are Average Wholesale Prices ("AWP") as established and made available to the public by a third party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class."

3. "The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included."

VII. Submissions to Attorney General Upon Request

Pharmaceutical Marketers shall, upon 10 days notice, submit to the Vermont Attorney General the Long Form and Short Form Disclosures they are using to make the required disclosures pursuant to the Pharmaceutical Marketers Price Disclosure Law and this Guide.

Information for Vermont Prescribers of Prescription Drugs

AUGMENTEV XR (amoxicillin/clavulanate potassium) Extended Release Tablets ,TM

This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.

The prices listed below are Average Wholesale Prices ("AWP") as established and made available to the public by a third party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.

The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

				AWP	
Product Name	**Manufacturer**	**NDC** or **UPC**	**Pkg Size**	**Pack**	**Tab**
Marketed Product					
AUGMENTIN XR TAB SR 12HR	GLAXO SMITHKLINE	00029-6096-48	28 EA	$87.71	$3.13
Other Products					
AMOX/K CLAV CHW 200MG	IVAX PHARMACEUTICALS, INC.	00172-7401-28	20 EA	$36.19	$1.81
AMOX/K CLAV CHW 200MG	RANBAXY PHARMACEUTICALS	63304-0753-20	20 EA	$37.20	$1.86
AMOX/K CLAV CHW 200MG	SANDOZ	00781-1619-66	20 EA	$36.17	$1.81
AMOX/K CLAV CHW 400MG	IVAX PHARMACEUTICALS, INC.	00172-7402-28	20 EA	$68.95	$3.45
AMOX/K CLAV CHW 400MG	RANBAXY PHARMACEUTICALS	63304-0754-20	20 EA	$70.88	$3.54
AMOX/K CLAV CHW 400MG	SANDOZ	00781-1643-66	20 EA	$68.93	$3.45
AMOX/K CLAV TAB 500MG	IVAX PHARMACEUTICALS, INC.	00172-7403-42	20 EA	$75.70	$3.79
AMOX/K CLAV TAB 500MG	LEK PHARMACEUTICALS INC.	66685-1002-02	100 EA	$367.10	$3.67
AMOX/K CLAV TAB 500MG	RANBAXY PHARMACEUTICALS	63304-0713-20	20 EA	$75.69	$3.78
AMOX/K CLAV TAB 500MG	SANDOZ	00781-1831-20	20 EA	$75.69	$3.78
AMOX/K CLAV TAB 500MG	TEVA PHARMACEUTICALS USA	00093-2274-34	20 EA	$75.69	$3.78
AMOX/K CLAV TAB 875MG	IVAX PHARMACEUTICALS, INC.	00172-7404-42	20 EA	$101.05	$5.05
AMOX/K CLAV TAB 875MG	LEK PHARMACEUTICALS INC.	66685-1001-01	100 EA	$490.00	$4.90
AMOX/K CLAV TAB 875MG	RANBAXY PHARMACEUTICALS	63304-0509-01	100 EA	$501.00	$5.01
AMOX/K CLAV TAB 875MG	SANDOZ	00781-1852-20	20 EA	$101.03	$5.05
AMOX/K CLAV TAB 875MG	TEVA PHARMACEUTICALS USA	00093-2275-34	20 EA	$101.03	$5.05
AMOXICILLIN CAP 250MG	AMERICAN HEALTH PACKAGING	62584-0237-01	100 EA	$26.29	$0.26
AMOXICILLIN CAP 250MG	RANBAXY PHARMACEUTICALS	63304-0654-01	100 EA	$24.97	$0.25
AMOXICILLIN CAP 250MG	SANDOZ	00781-2020-01	100 EA	$24.89	$0.25
AMOXICILLIN CAP 250MG	STADA PHARMACEUTICALS, INC.	55370-0884-07	100 EA	$24.94	$0.25
AMOXICILLIN CAP 250MG	STADA PHARMACEUTICALS, INC.	67253-0140-10	100 EA	$24.94	$0.25
AMOXICILLIN CAP 250MG	TEVA PHARMACEUTICALS USA	00093-3107-01	100 EA	$25.00	$0.25
AMOXICILLIN CAP 250MG	UDL	51079-0600-20	100 EA	$26.10	$0.26
AMOXICILLIN CAP 500MG	AMERICAN HEALTH PACKAGING	62584-0238-01	100 EA	$49.09	$0.49
AMOXICILLIN CAP 500MG	IVAX PHARMACEUTICALS, INC.	00172-7414-70	500 EA	$184.55	$0.37
AMOXICILLIN CAP 500MG	RANBAXY PHARMACEUTICALS	63304-0655-01	100 EA	$43.41	$0.43
AMOXICILLIN CAP 500MG	SANDOZ	00781-2613-01	100 EA	$43.41	$0.43
AMOXICILLIN CAP 500MG	STADA PHARMACEUTICALS, INC.	55370-0885-07	100 EA	$58.75	$0.59
AMOXICILLIN CAP 500MG	TEVA PHARMACEUTICALS USA	00093-3109-53	50 EA	$23.35	$0.47
AMOXICILLIN CAP 500MG	UDL	51079-0601-20	100 EA	$49.00	$0.49
AMOXICILLIN CHW 125MG	RANBAXY PHARMACEUTICALS	63304-0514-01	100 EA	$24.65	$0.25
AMOXICILLIN CHW 125MG	TEVA PHARMACEUTICALS USA	00093-2267-01	100 EA	$22.50	$0.23
AMOXICILLIN CHW 125MG	WARRICK PHARMACEUTICALS	59930-1573-02	100 EA	$11.00	$0.11
AMOXICILLIN CHW 125MG	WARRICK PHARMACEUTICALS	59930-1573-03	500 EA	$52.25	$0.10
AMOXICILLIN CHW 200MG	RANBAXY PHARMACEUTICALS	63304-0760-20	20 EA	$8.93	$0.45
AMOXICILLIN CHW 250MG	PUREPAC	00228-2640-25	250 EA	$57.00	$0.23
AMOXICILLIN CHW 250MG	RANBAXY PHARMACEUTICALS	63304-0515-01	100 EA	$45.00	$0.45
				AWP	

Product Name	Manufacturer	NDC or UPC	Pkg Size	Pack	Tab
AMOXICILLIN CHW 250MG	STADA PHARMACEUTICALS, INC.	55370-0892-07	100 EA	$22.90	$0.23
AMOXICILLIN CHW 250MG	TEVA PHARMACEUTICALS USA	00093-2268-01	100 EA	$45.00	$0.45
AMOXICILLIN CHW 250MG	WARRICK PHARMACEUTICALS	59930-1611-01	60 EA	$13.75	$0.23
AMOXICILLIN CHW 400MG	IVAX PHARMACEUTICALS, INC.	00172-7416-60	100 EA	$54.55	$0.55
AMOXICILLIN CHW 400MG	RANBAXY PHARMACEUTICALS	63304-0761-01	100 EA	$54.56	$0.55
AMOXICILLIN SUS 250/5ML	IVAX PHARMACEUTICALS, INC.	00172-7418-21	100 EA	$6.10	$0.06
AMOXICILLIN TAB 500	RANBAXY PHARMACEUTICALS	63304-0762-20	20 EA	$11.70	$0.58
AMOXICILLIN TAB 500	TEVA PHARMACEUTICALS USA	00093-2263-01	100 EA	$49.81	$0.50
AMOXICILLIN TAB 875MG	IVAX PHARMACEUTICALS, INC.	00172-7411-60	100 EA	$87.25	$0.87
AMOXICILLIN TAB 875MG	RANBAXY PHARMACEUTICALS	63304-0763-01	100 EA	$87.16	$0.87
AMOXICILLIN TAB 875MG	TEVA PHARMACEUTICALS USA	00093-2264-01	100 EA	$87.21	$0.87
AMOXIL CAP 500MG	GLAXO SMITHKLINE	00029-6007-30	100 EA	$40.40	$0.40
AMOXIL CHW 200MG	GLAXO SMITHKLINE	00029-6044-12	20 EA	$10.15	$0.51
AMOXIL CHW 400MG	GLAXO SMITHKLINE	00029-6045-12	20 EA	$12.40	$0.62
AMOXIL TAB 500MG	GLAXO SMITHKLINE	00029-6046-20	100 EA	$55.35	$0.55
AMOXIL TAB 875MG	GLAXO SMITHKLINE	00029-6047-20	100 EA	$96.90	$0.97
AMPICILLIN CAP 250MG	SANDOZ	00781-2144-01	100 EA	$23.46	$0.23
AMPICILLIN CAP 250MG	STADA PHARMACEUTICALS, INC.	55370-0880-07	100 EA	$21.11	$0.21
AMPICILLIN CAP 250MG	TEVA PHARMACEUTICALS USA	00093-5145-01	100 EA	$23.46	$0.23
AMPICILLIN CAP 500MG	SANDOZ	00781-2145-01	100 EA	$39.88	$0.40
AMPICILLIN CAP 500MG	STADA PHARMACEUTICALS, INC.	55370-0881-07	100 EA	$35.89	$0.36
AMPICILLIN CAP 500MG	TEVA PHARMACEUTICALS USA	00093-5146-01	100 EA	$39.88	$0.40
AUGMENTIN CHW 125MG	GLAXO SMITHKLINE	00029-6073-47	30 EA	$47.26	$1.58
AUGMENTIN CHW 200MG	GLAXO SMITHKLINE	00029-6071-12	20 EA	$45.73	$2.29
AUGMENTIN CHW 250MG	GLAXO SMITHKLINE	00029-6074-47	30 EA	$90.15	$3.00
AUGMENTIN CHW 400MG	GLAXO SMITHKLINE	00029-6072-12	20 EA	$87.15	$4.36
AUGMENTIN TAB 250MG	GLAXO SMITHKLINE	00029-6075-31	100 EA	$333.20	$3.33
AUGMENTIN TAB 500MG	GLAXO SMITHKLINE	00029-6080-31	100 EA	$490.33	$4.90
AUGMENTIN TAB 875MG	GLAXO SMITHKLINE	00029-6086-21	100 EA	$654.49	$6.54
PRINCIPEN CAP 250MG	SANDOZ	00003-0122-50	100 EA	$23.46	$0.23
PRINCIPEN CAP 500MG	SANDOZ	00003-0134-50	100 EA	$39.88	$0.40
TRIMOX CAP 250MG	SANDOZ	00003-0101-50	100 EA	$24.89	$0.25
TRIMOX CAP 500MG	SANDOZ	00003-0109-55	100 EA	$43.41	$0.43

First DataBank is the source of this information.

[date]

Appendix 2 - Short Form Disclosure Model

Information for Vermont Prescribers of Prescription Drugs (Short Form)

Augmentin XR (amoxicillin/clavulanate potassium) Extended Release Tablets

- This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.
- The prices listed below are Average Wholesale Prices ("AWP") as established and made available to the public by a third party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
- The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

PriCG Comparison: Marketed product and lowest dosage of other products in same therapeutic class.*

Marketed Product:	
Augmentin XR Tab SR 12 hr	$3.13
Other Products:	
Ampicillin Cap250mg	$0.22
Principen Cap 250mg	$0.23
Amoxicillin CAP 250mg	$0.25
Trimox Cap 250mg	$0.25
Amoxil Cap/Tab 500mg	$0.47
Augmentin Tab 250mg	$3.33
Amox/K Clav Tab 500 mg	$3.76

*Prices shown are for the lowest dosage of each product. Prices for multi-source products have been averaged. Multiple forms of the same product (e.g. tabs and caps) have been considered one product, and the prices have been averaged. Chewable forms of the product are not included.

For additional price comparison information see: http:// [INSERT WEB ADDRESS WHERE LONG FORM DISCLOSURE SHALL BE AVAILABLE]

AHFS PHARMACOLOGIC-THERAPEUTIC CLASSIFICATION

4:00 Antihistamine Drugs

4:04 First Generation Antihrstanilhes ■»
4:04104' Ethanolamine Derivatives* •■ ■
4*04:08 -EthylenediamineDerivmiyes*-4:04.12
Pheno.thiazine Derivatives* 4:04.16
PigerEaine Derivatives* 4:04.20 Propyfamine
Derivatives* , *4:04.92* Miscellaneous
Derivatives*
4:08 Second Generation Arifihistamih6s'
4:92 Other Antihistamines*

8:00 Anti-infective Agents

8:08 Anthelmintics
8:12 Antiba
8:12.02 cterial
8:12.06 s
Aminoglycosides
Cephalosporins
8:12.06.04 First Generation Cephalosporins.
8:12.06.08 Secondr.Qeneration Cephalosporins.
8:12.06.12 Third GeneratioD/Cephalosporins "
8:12.06.16 Fourth Generation Gephalosporins
8:12.07 Miscellaneous #-Lactams, ■■■■
8:12.07.04 Carbacephem.'
8:12.07.08 , Carbapenenis;
8:12.07.12 Cepharaycins
8:12.07 16 Monobactams
8:12.08 Chloramphenicol
8:12,12
8:12.12.04
8:12.12.92
Penicillins
8:12.16.04
8:12.16.08
8:12.16.12
8:12.16.16 Quinolones
Sulfonaraides Tetracyclines
Miscellaneous Anti&acferials
8:12.28.04 Arninocyclitofe-
8:12.28.08 Bacitracins
8:12.28.12 Cyclic Lipopeptides

Macrolides
Erythromycins
Other Macrolides
8:12.16
Natural Periibillias Aminopenicillins
PenicillinaSe-resistaritPehkillinS
Extended-spectruiii Penicillins •
8:12.18
8:12:20
8:12.24
8:12.28
§^
8:12.28.20 Lincomycms' ■ ′.
8:12.28.24 Oxazolidinones
8;12.28,2.8 Polymyxins .
8;12.2i8'.32 ■Streptogfamins
8:12.28.92 Other Miscellaneous Antibacterial
Agents* Antif ungals
8:14 8:14.04 Allylamines 8:14.08 Azoles 8:14.16
Echinqcaijdms 8:14.28 Pc-iyenes .
8:14.32 Pyrimjdiiies. 8:14.92

8:30

Misceilanebus Antifungals
Antimycobacterlals 8; 16.04
Atttitube'rculosis Agents 8:16.92
Miscellaneous Antimyco.bacterials Antivirals
8:18.04 Adamantanes

12:12
12:16
12:20
12:92

8:18

8:18.08 Antiretrovirals.
8:18.08.04 HIV Fusion Inhibitors
8:18.08.08 HIV Protease .Inhibitors
8:18.08.12 •■ Integrase Inhibitors* .
8:18.08.16c-■ -Nonnflcleo^ide Reverse. Transcriptase Inhibitors- -
8:18.08.20 Nucleoside and Nucieotide Reverse [1] TtahscriptaseinSiibirors
8:18:08.92 ■ Miscdlaneoiis Amiretrovirsls*
8:18,20- "Iriterferons
8:18.24 Monoclonal *i* Vntibodies
8:18,28 Neuraminidase'Inhibito'rs
S; 18,32 Nucleosides and Nucleotides
8:18.92 Miscellaneous Aritivirats
Antiproiozoals
8:30;04

8:30.'92 Misceilaheous Antiprotozoals Ursnavv
AnfririteotWes' 8:92 Miscellaneous Anti-infective^*'

10:00 Antiqeaptestic; Agentg ^

12:00 Autonomlc Drugs u

12:04 Pa ra^yfnpathomlmef ic (Choliner&ic)' Agenis
12:06 Antichblinerglc Agents 12:08.04
Antiparkinsomai) Agents 12:08.06
Aritimuscarinics/Anrispasraodics
Sympatripmirn.etic (Adrenergic) Agents
Sympathotytic (Adrenergic Blocking) Agents
Skeletal Muscle Relaxants MJscallanepus
Autonomic Drugs

16:0 Blood Derivatives

20:0 Blood Formation and Coagulation

20:04 Antianemia Drugs
20:04.04 Iron Preparations '
20:04.08 Liver dhd Stomach Preparations
20:12 Coagulants and Anticoagulants
20:12.04 , Anticoagulanls
20:12.04.08. Coumarin and Indandione .. Derivatives
20:,l-2.<H.l,6 Heparin^
•20:12.04,92 Miscellaneous Anticoagulants
■2D:i2.08 , Antiheparin Agents
2Q:lZ.n .- Coagulatita
20:12.16 Hemostatics
20:16 Hematopoietlc Agents. ■
20:24 Hemorrheojogio Agenis,
20:40 Thrombolylic Agents. "

24:0 Cardiovascular Drugs

24:04 Cardiac.Drugs .
24:04.04 Antiarrhyshmic Agents 24:04,08
Cardietonie Agenis ., 24:04.40
Miscellaneous Cardiac Drugs*

24:06' Antilipemic Agents
- 24:06.04 Bile Acid Sequestrants
- 24:06.06 Fibric Acid Derivatives
- 24:06.08 HMG-CoA Reduclase Inhibitors
- 24:06.92 Miscellaneous Antilipemic Agents

24:08 Hypertensive Agents
- 24:08-16 Central-a-Agonists
- 24:08.20 Direct Vasodilators
- 24:08.32 Peripheral Adrenergic Inhibitors
- 24:08.92 Miscellaneous Hypotensive Agents*

24:12 Vasodilating Agents
- 24:12.08 . Nitrates and Nitrites
- 24:12.12 ■ Phosphodiesterase Inhibitors
- 24:12.92 Miscellaneous Vasodilating Agents.

24:16 Sclerosing Agents 24:20 a-Adrenergic Blocking Agents 24:24 /3-Adrenergic Blocking Agents

24:28 Calcium-Channel Blocking Agents
- 24:28.08 Dihydropyridines
- 24:28.92 Miscellaneous Calcium-Channel Blocking Agents

24:32 Renin-Angiotensin-Aldosterone System Inhibitors
- 24:32.04 Angiotensin-Converting Enzyme Inhibitors
- 24:32.08 Angiotensin II Receptor Antagonists
- 24:32,20 Mineralocorticoid (Aldosterone) Receptor Antagonists

28:00 Central Nervous System Agents ' '

28:04 General Anesthetics

28:08 Analgesics and Antipyretics
- 28:08.04 Nonsteroidal Anti-inflammatory Agents
  - 28:08.04.08 Cyclooxygenase-2 (COX-2) Inhibitors
  - 28:08.04.24 Salicylates
- 28:08.04.92 "Other Nonsteroidal Anti-inflammatory Agents 28:08.08 Opiate Agonists 28:08.12 Opiate Partial Agonists 28:08.92 Miscellaneous Analgesics and Antipyretics Opiate Antagonists Anticonvulsants
- 28:12,04 Barbiturates 28:12.08 Benzodiazepiries'

28:10 28:12.12 Hydantoins 28:12.16 Oxazolidinediones

28:12 28:12.20 Siiccinimides 28:12.92 Miscellaneous Anticonvulsants Psychotherapeutic Agents 28:16,04 Antidepressants
- 28' 16.04.12 Monoamine Oxidase Inhibitors
- 28:16.04.20 Selective-serotonin Reuptake Inhibitors
- 28:16.04.24 Serotonin Modulators

28:16 28:16.04.28 Tricyclics and Other Norepinephrine-reuptake Inhibitors
- 28:16.04.92 Miscellaneous Antidepressants

28:16.08 Antipsychotics
- 28:16.08.04 Atypical Antipsychotics '
- 28:16.08,08 Butyrophenones '
- 28:16.08,24 Phenothiazines
- 28.16;08.32 Thioxanthenes ..
- 28:16,08.92 Miscellaneous Antipsychotics

28:16.12 Miscellaneous Psychotherapeutic Agents*

28:20 Anorexigenic Agents and Respiratory and Cerebral Stimulants

28:24 Anxiolytics, Sedatives, and Hypnotics
- 28:24.04 Barbiturates
- 28:24.08 •■ Bsnzoctiazepines
- 28:24.-92 • Miscellaneous Anxiolytics, Sedatives-, and Hypnotics

28:28 Antimanlo Agents., .. ,,,_ .,, . , . . . , . .

28:92 Miscellaneous Central Nervous System Agents'

32:0 Contraceptives (foams, devices)*

34:0 Dental Agents'*

36:0 Diagnostic Agents

36:04 Adrenocortlcal Insufficiency?
36:08 AmyloldosisS
36:12 Blood. VolumeS
36:16 Brucellosis§
36.18 Cardiac Functions'
36:24 Circulation Time?
36;26 Diabetes MellitusS
36:28 Diphtherias
36:30 Drug Hypersensitivity?
36:32 Fungi?-
36:34 Gallbladder Functions
36:36 Gastric Functions
36:38 Intestinal Absorptions
36:40 Kidney Function?
36:44 Liver Function?
36:48 Lymphogranuloma VenereumS
36:52 Mumps?
36:56 Myasthenia GravlsS
36:60 Thyroid Functions
36:61 Pancreatic Functions
36:62 PhenylketonuriaS
36:64 Pheochromocytoma?
36:66 Pituitary Function?
36:68 Roentgenography?
36:72 Scarlet Fever?
36:76. Sweating? .
36:80 TrichinoslsS
36:84 Tuberculosis
36:88 Urine and Feces Contents*
- 36:88.12 Ketones*
- 36:88.20 Occult Blood*
- 36:88.24 pH*
- 36:88.28 Protein*
- 36:88.40 Sugar*

38:0 Disinfectants (for agents used on objects othe than skin)

40:0 Electrolytic, Caloric, and Water Balance

40:04 Acidifying Agents
40:08 Alkalinizing Agents
40:10 Ammonia Detoxicants
40:12 Replacement Preparations
40:18 Ion-removing Agents
- 40:18.16 Sodium-removing Agents*
- 40:18.17 Calcium-removing Agents
- 40:18.18 Potassium-removing Agents
- 40:18.19 Phosphate-removing Agents
- 40:18.92 Other Ion-removing Agents

40:20 Caloric Agents
40:24 Salt and Sugar Substitutes
40:28 Diuretics
- 40:28.10 Potassium-sparing Diuretics

40:36 irrigating Solutions
40:40 Uricosurjq Agents

44:00 Enzymes

48:00 Antitussives, Expectorants, and Mucoiytic Agents

48:08 Antitussives, ,.
48:16 Expectorants .
48:24 Mucolylic Agenjs.

52:00 Eve. Ear. Nose. and Throat (EENT) Preparations

52:02 Antiallergic Agents
52:04 Anti-infectives
"52:04.04 Antibacterials ■
52:04.16 Antifungals
52:04.20 Antivirals
52:04.92 . Miscellaneous Anti-infectives
52:08 Anti-inflammatory Agents
S2'10 Carbonic Anhydrast* inhibitors
52:12 Contact Lens Solutions
52:16 Local Anesthetics
52:20 Mlotics 52:24 Mydriatlcs
52:28 Mouthwashes and Gargles
52:32 Vasoconstrictors
52:36 Miscellaneous EENT Drugs

56:00 Gastrointestinal Drugs

56:04 Antacids and Adsorbents
56:08 Antidlarrhea Agents
56:10 Antiflatulents
56:12 Cathartics and Laxatives
56:14 Cholelitholytic Agents
56:16 Digestants
56:20 Emetics
56:22 Antiemetics
56:22.08 Antihistamines
56:22,20 5-HT3 Receptor Antagonists
56:22,92 Miscellaneous Antiemetics
56:24 Lipotroplc Agents*
56:28 Antiulcer Agents and Acid Suppressants
56:28.12 Bistamine H2-Antagonists
56:28.28 Prostaglandins
56:28.32 Protectants
56:28,36 Proton-pump Inhibitors
56:32 Proklnetic Agents
56:36 Anti-Inflammatory Agents
56:92 Miscellaneous GI Drugs

60:00 Gold Compounds

64:00 Heavy Metal Antagonists

68:00 Hormones and Synthetic Substitutes

68:04 Adrenals
68:08 Androgens
68:12 Contraceptives
68:16 Estrogens and Antiestrogens
68:16.04 Estrogens
68:16.08 Antiestrogens*
68:16.12 Estrogen Agonists-Antagonists
'68:18 "(aonadbtropins, ;:.:,,.
68:20 ■ Antldiabetic Agents
68.20.02-r'< ff-Glucosidase-Inhibitors
68.20.04 BigiiaMdes ■ ■ ■ . - ' ■ '
68:20.08 Insulins- "
.,63:20.16- - MegHtmides
68:20.20 Sulfonylureas
68:20.92 Miscellaneous Antidiabetic Agents
68:24 Parathyroid
68:28 Pituitary
68:30 Somatotropin Agonists and Antagonists
68:30.04 Somatotropin Agonists*
68:30.08 Somatotropin Antagonists
68:32 Progestins
•66:34- ©ther Corpus b.uteam Hormones*
6.8:36. . Thyroid arid AMithyrotd Agents
68:36.04 Thyroid Agents
6*8:36.08 ""Anttthyroid Agents

72:0C 1 Local Anesthetics

76:0C > Oxytocics

78:0C) Radioactive Agents*

80:0C) Serums, Toxoids, and Vaccines

80:04 Serums
80:08 Toxoids
80:12 Vaccines

84:0C) Skin and Mucous Membrane Agents

84:04 Anti-infectives
84:04,04 Antibacterials
84:04.06 Antivirals
84:04.08 Antifungals
84:04.08.04 Allylamines
84:04.08.08 Azoles
84:04.08.12 Benzylamines
84:04.08.56 Bchinocandins*
84:04.08.20 Hydroxypyridones
84:04.08.28 Polyenes
84:04.08.32 Pyrimidines*
84:04.08.40 Thiocarbamates
84:04.08.92 Miscellaneous Antifungals
84:04.12 Scabicides and Pediculicides
84:04.16 Miscellaneous Local Anti-infectives
84:06 Anti-inflammatory Agents
84:08 Antipruritics and Local Anesthetics
84:12 Astringents
84:16 Cell Stimulants and Proliferants
84:20 Detergents
84:24.04 Basic Lotions and Liniments*
84:24.08 Basic Oils and Other Solvents*
84:24.12 Basic Ointments and Protectants*
84:28 Keratolytlc Agents
84:32 Keratoplastic Agents
84:36 Miscellaneous Skin and Mucous Membrane Agents
84:50 Depigmenting and Pigmenting Agents
84:50.04 Depigmenting Agents
84:50.06 Pigmenting Agents
84:80 Sunscreen Agents§

86:00 Smooth Muscle Reiaxants

86:08 Gastrointestinal Smooth Muscle Reiaxants
86:12 Genitourinary Smooth Muscle Reiaxants 86:16 Respiratory Smooth Muscle Reiaxants

88:00 Vitamins

88:04 Vitamin A
88:08 Vitamin B Complex
88:12 Vitamin C
88:16 Vitamin D
88:20 Vitamin E
88:24 Vitamin K Activity .
88;28 Multivttamin Preparations

92:00 Miscellaneous Therapeutic Agents

94:00 Devices*

96:00 Pharmaceutical Aids*

For the 2004 edition of *AHFS Drug Information',* the AHFS Pharmacologic-Therapeutic Classification for sections 4:00 Antihisramines, 8:00 Anti-infective Agents, 20:00 Blood Formation and Coagulation, 24:00 Cardiovascular Drugs, 28:00 Central Nervous System Agents, 52:00 EENT Preparations, 68:00 Hormones and Synthetic Substitutes, and- 84:00 Skin and Mucous Membrane Agents have been reorganized based on extensive research and review, including substantial feedback from users of the classification. *Tha* newly reorganized classification provides substantially greater specificity for various classes of drugs, retaining a combination ofpharmacologic and therapeutic subclasses. Users of the classification can use either the 'primary classes or the secondary classes (i.e., the' class under which the drug in question is cross-referenced) or both, depending on their need. In electronic versions *of AHFS Drug Information',* both the primary and secondary classes are used.

* Category is currently not in use in the printed version of *AHFS Drug Information'*

§ Omitted from the print version of *AHFS Drug Information* because of space limitations. Copies of these monographs are available on the *AHFS Drug Information* web site, http://www.ahfsdruginformation.com. See the Preface for details on accessing this site.